Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN002 gel for non-melanoma skin cancer and precancerous skin lesions
ACTRN12623001219673Phase 2Recruiting
- Sponsor
- Enkang Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of EN002-gel in basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), actinic keratosis (AK) and 1 more, sponsored by Enkang Pharmaceuticals. Primary endpoints: Safety, Toxicity laboratory assessment and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
EN002-gel
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)actinic keratosis (AK)Bowen disease (BD)
Beyond the preview
Go deeper on ACTRN12623001219673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001219673.